• History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis). • Requires whole blood transfusion to me et eligibility criteria. • Inadequate organ function, evidenced by the following laboratory results: − White blood cell (WBC) count < 3,500 cells/mm3 − Absolute neutrophil count < 1,500 cells/mm3. − Platelet count < 100,000 cells/mm3. − Hemoglobin < 9 g/dL. − Total b ilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert’s syndrome). − Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases). − Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases). − Serum creatinine > 2.0 mg/dL or 177 μmol/L. − International normalized ratio (INR) or activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) >1.5 × ULN (unless on therapeutic anti- coagulation). • Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/ stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. • Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. • Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). • Current chronic daily treatment (continuous f or > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. • Known hypersensitivity to any component of the study medication(s). • Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. See Excluded Medications list. Confidential and Proprietary 10 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 • Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone- lowering therapy in men with prostate cancer. • Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol. • Concurrent participation in any interventional clinical trial.